Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQUENCE: Sequential Gilteritinib + Venetoclax + Azacitidine in FLT3-mutated AML Ineligible for Intensive Therapy
2023-507878-41-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gilteritinib, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Ratio of dose delivered/dose planned over 12-cycle treatment period. Planned start Aug 2024; status: authorised.
02
Drugs
gilteritinibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-507878-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507878-41-00.